Open AccessThe next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?
Author(s) -
Laurens F. Reeskamp,
Tycho R. Tromp,
Erik S.G. Stroes
Publication year - 2020
Publication title -
current opinion in lipidology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.412
H-Index - 124
eISSN - 1473-6535
pISSN - 0957-9672
DOI - 10.1097/mol.0000000000000679
Subject(s) - apolipoprotein b , triglyceride , medicine , lipoprotein , microsomal triglyceride transfer protein , endocrinology , pharmacology , pcsk9 , cholesterol , very low density lipoprotein , ldl receptor
Apolipoprotein C-III (ApoC-III) and angiopoietin like protein 3 (angptl3) have emerged as key regulators of triglyceride metabolism. Based on Mendelian randomisation studies, novel therapeutic strategies inhibiting these proteins using monoclonal antibodies or gene silencing techniques might reduce residual cardiovascular disease (CVD) risk in dyslipidemic patients. This article aims to review the role of apoC-III and angptl3 in triglyceride metabolism and combine early clinical evidence of CVD reducing potential of these new therapeutic targets.